Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales up 12% on prior quarter Canada Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp) Q1 sales up 63% on prior quarter USA Q1 sales AUD$0.3 million down 19% on prior comparative period (pcp) Q1 sales down 24% on prior quarter MELBOURNE, Australia , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce double digit sales growth (unaudited) in the quarter ending September 30, 2026 . Continued Travelan® Australian sales growth in Q1 FY27 ( +14% on pcp ) in Australia can be attributed to the new Travelan® brand re-launch, including new packaging and associated brand communications which has resonated strongly with consumers and has been well received and supported by all the major pharmacy banner groups. Travelan® is one of the fastest growing anti-diarrhoeals & digestive health brands in Pharmacy, growing at 26.4% versus category growth of 5.3%, and in the last 13 weeks exceeding well-known brands, such as Imodium®, in total pharmacy sales, ( IQVIA scan sales, 13 weeks to 26 Sep 2026 ). Immuron continues to increase market penetration of PROIBS® which is now stocked by the largest wholesaler, Sigma and is now available in Amcal and DDS pharmacies. Sales in the U.S . decreased in Q1 FY27 ( -19% on pcp ) due to higher purchases during Amazon Prime Day in June 2026 as well as customs and logistics challenges delaying replenishment of US inventory. Inventory is now replenished. There is a positive outlook for the next quarter with Amazon Prime days in October and Thanksgiving , Black Friday and Cyber Monday in November. Continued Travelan® Canadian sales growth in Q1 FY27 ( +286% on pcp ) in Australia can be attributed to increased brand awareness and product sampling at the Shoppers Drug Mart conferences in Toronto and Calgary . Shoppers Drug Mart is Canada’s largest drugstore chain. July 2026 was Travelan’s highest non-pipeline sales month in Canada . This release has been authorised by the directors of Immuron Limited . COMPANY CONTACT: Steven Lydeamore Chief Executive Officer steve@immuron.com About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. About Travelan® Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. Travelers’ diarrhea (TD) TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations ( Leung et al., 2006 ). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions ( Steffen, 2017 ). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they seek care and treatment ( Connor et al., 2012 ). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies ( Riddle et al., 2006 ). Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (G